Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Stacey A Cohen and Dr Arvind Dasari, moderated by Dr Bekaii-Saab, including the following topics:

• Introduction (0:00)
• Current and Future Role of Immune Checkpoint Inhibition in the Management of Microsatellite Instability-High/Mismatch Repair Deficient Localized and Locally Advanced Colorectal Cancer (CRC) — Dr Cohen (1:45)
• Clinical Relevance and Practical Utilization of Molecular Residual Disease Analysis in CRC — Dr Dasari (34:08)
• Recent Advances in Metastatic CRC: Optimizing Immunotherapy and Other Approaches — Dr Bekaii-Saab (1:00:42)

CME information and select publications

Featuring perspectives from Dr Mazyar Shadman, including the following topics:

• The CLL17 trial: Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia (CLL) (0:00)
• The AMPLIFY trial: Fixed-duration acalabrutinib combinations for untreated CLL (5:31)
• Zanubrutinib-based therapy for treatment-naïve CLL (12:32)

CME information and select publications

Featuring perspectives from Dr Mazyar Shadman and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:

• Case: A man in his mid 40s with chronic lymphocytic leukemia (CLL) receives acalabrutinib/venetoclax as part of the MAJIC trial (0:00)
• Case: A man in his early 70s with TP53-mutated CLL expresses concern about side effects associated with zanubrutinib (8:22)
• Case: A man in his late 70s with Stage IIIB chronic kidney disease and CLL receives obinutuzumab (18:02)

CME information and select publications